作者: Jiagen Wen , Meizi Zeng , Zhaoqian Liu , Honghao Zhou , Heng Xu
DOI: 10.1016/J.JPHS.2018.11.007
关键词: Pharmacokinetics 、 Metformin 、 Insulin 、 Medicine 、 Side effect 、 Pharmacodynamics 、 Pharmacology 、 Crossover study 、 Cmax 、 Telmisartan
摘要: Abstract Metformin is the most widely used drug among type 2 diabetes mellitus patients. However, interaction on metformin will influence its glucose-lowering effect or increase side of lactic acidosis. In this study, a randomized, two-stage, crossover study was conducted to unveil potential between and anti-hypertension drug, telmisartan. Totally, 16 healthy Chinese male volunteers were enrolled. Blood samples from various time-points after adminstration analyzed for quantification. Oral glucose tolerance test (OGTT) 2 h administration. The AUC0-12 Cmax in subjects co-administrated with telmisartan significantly lower than placebo. geometric mean ratios (value plus phase/value placebo phase) 0.7972 (90%CI: 0.7202–0.8824) 0.8336 0.7696–0.9028), respectively. Moreover, co-administration increased plasma concentrations both insulin at 0.5 h since OGTT (7.64 ± 1.86 mmol/l·min vs 6.77 ± 0.83 mmol/l·min, P = 0.040; 72.91 ± 31.98 μIU/ml·min 60.20 ± 24.20 μIU/ml·min, P = 0.037), though AUC showed no significant difference. These findings suggested that had Pharmacokinetics groups, moderate.